v3.20.2
Condensed Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Jun. 30, 2020
Dec. 31, 2019
Current assets:    
Cash and cash equivalents $ 65,348 $ 4,960
Marketable securities 136,015 112,904
Investment in equity securities 49,094  
Accounts receivable (including amounts from related parties of $0 and $1,050 as of June 30, 2020 and December 31, 2019, respectively) [1] 5,102 6,298
Prepaid expenses and other current assets 2,931 4,406
Total current assets 258,490 128,568
Property and equipment, net 11,265 9,633
Marketable securities, non-current 5,647 15,609
Other non-current assets 2,121 2,545
Restricted cash 15 15
Total assets 277,538 156,370
Current liabilities:    
Accounts payable 4,901 5,584
Accrued compensation 4,520 6,017
Deferred revenue—current 23,503 19,465
Debt—current   1,000
Other current liabilities 2,536 901
Total current liabilities 35,460 32,967
Deferred revenue, non-current 10,562 16,195
Deferred rent 330 409
Debt—non-current 24,281 8,876
Other noncurrent liabilities 148 134
Total liabilities 70,781 58,581
Stockholders’ equity:    
Preferred stock, $0.001 par value — 10,000,000 shares authorized as of June 30, 2020 and December 31, 2019; 0 shares issued and outstanding as of June 30, 2020 and December 31, 2019
Common stock, $0.001 par value — 300,000,000 shares authorized as of June 30, 2020 and December 31, 2019; 35,878,928 and 23,098,969 shares issued and outstanding as of June 30, 2020 and December 31, 2019, respectively 36 23
Additional paid-in-capital 391,791 293,346
Accumulated other comprehensive income 398 165
Accumulated deficit (185,468) (195,745)
Total stockholders’ equity 206,757 97,789
Total Liabilities and Stockholders’ Equity $ 277,538 $ 156,370
[1] Merck was a related party until the closing of the Company’s public offering on May 14, 2020.
Vaxcyte (formerly SutroVax) was a related party until the closing of its initial public offering on June 16, 2020.

Source